Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Congress 2022 | Promising new MPN treatments

John Mascarenhas • 24 Nov 2022
MPN Congress 2022
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Bomedemstat Imetelstat KRT-232 Navtemadlin Selinexor Tagraxofusp

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York City, NY, gives a presentation on promising new treatments for myeloproliferative neoplasms (MPNs) at the 14th International Congress on Myeloproliferative Neoplasms held in New York City, NY.

More from John Mascarenhas

1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
1:30
MDM2 inhibitors in myelofibrosis treatment: the addition of navtemadlin to ruxolitinib
John Mascarenhas • 10 Dec 2023
1:18
Immunotherapeutic approaches in CALR-mutated MPNs
John Mascarenhas • 9 Sep 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals